Grufity logoGrufity logo

IOVA

6.18USD-0.04(-0.64%)Delayed

Iovance Biotherapeutics Inc

Market Summary

USD6.18-0.04Delayed
-0.64%

IOVA Stock Price

RSI Chart

Valuation

Market Cap

1.5B

Price/Earnings

-4.09

Price/Cashflow

-5.85

Price/Sales

Profitability

Return on Equity

-79.63%

Return on Assets

-61.62%

Fundamentals

Revenue

Earnings

Earnings (TTM)

-376.4M

Earnings Y/Y

-22.12%

Earnings Q/Q

-8.46%

Price Action

52 Week Range

5.4220.60
(Low)(High)

Last 7 days

-6.6%

Last 30 days

-36.2%

Last 90 days

-43.8%

Trailing 12 Months

-67.0%

Financial Health

Current Ratio

6.72

Investor Care

Shares Dilution (1Y)

1.94%

Diluted EPS (TTM)

-2.39

Peers (Alternatives to Iovance Biotherapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
146.5B
26.3B
7.14% 43.50%
22.27
5.55
2.18% 21.86%
99.4B
27.1B
21.80% 28.96%
24.02
3.61
-1.26% -54.91%
59.1B
23.0B
24.23% -35.48%
4.2
2.57
227.55% 302.16%
41.3B
10.4B
8.82% 22.00%
14.4
3.98
-6.64% 85.32%
11.1B
1.4B
7.16% 39.03%
905.99
8.52
29.86% -86.92%
MID-CAP
3.7B
112.4M
7.23% -37.09%
-12.87
32.5
-41.50% -607.58%
3.4B
-
-6.88% -45.94%
-14.65
59.51
215916.67% 21.41%
2.0B
432.8M
-5.28% -44.88%
29.99
4.9
1042.97% 128.67%
SMALL-CAP
1.8B
1.8B
-27.49% -91.73%
-1.22
1.39
53.41% -22.97%
1.6B
69.7M
-21.14% -78.94%
-3.15
20.84
745.14% -7.72%
1.5B
-
-36.22% -66.97%
-4.09
-
-40.64% -32.64%
891.0M
3.2M
12.62% -35.50%
-6.7
275.59
11.14% -46.59%
458.1M
-
-23.83% -90.20%
-13.56
44.06
522.71% -129.91%
218.9M
-
-24.71% -82.02%
-2.36
609.63
-71.03% -64.56%
6.6M
1.6M
-7.72% -68.11%
-0.89
4.46
165.64% -38.13%

Financials for Iovance Biotherapeutics

Income Statement (Last 12 Months)
Description(%) Q/Q2019Q12018Q42018Q32018Q22018Q1
RevenueNaN%nullnullnullnullnull
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Assets-12.9%611701777829853
  Current Assets-11.9%432490508583667
    Cash Equivalents17.0%10892785983
  Net PPE-1.6%1011031018880
Liabilities-7.4%138149156130108
  Current Liabilities-16.7%6477896561
Shareholder's Equity-14.4%473552622698744
  Retained Earnings-7.9%-1,363.40-1,264.05-1,172.44-1,073.11-986.99
  Additional Paid-In Capital1.1%1,8391,8181,7951,7711,731
Shares Outstanding0.4%158157157157155
Float-3,800----
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Cashflow From Operations-9.9%-262,937.00-239,311.00-227,900.00-236,792.00-219,634.00
  Share Based Compensation10.7%83,14375,08969,76560,89352,293
Cashflow From Investing2701.4%264,3659,437132-10,453.00-76,156.00
Cashflow From Financing-87.2%24,272190,321239,268238,076218,470

Risks

What is the probability of a big loss on IOVA?

100%


Probability that Iovance Biotherapeutics stock will be more than 20% underwater in next one year

90.8%


Probability that Iovance Biotherapeutics stock will be more than 30% underwater in next one year.

77.3%


Probability that Iovance Biotherapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does IOVA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Iovance Biotherapeutics was unfortunately bought at previous high price.

Returns

Cumulative Returns on IOVA

-14.6%


10-Year Cumulative Returns

-2.1%


7-Year Cumulative Returns

-7.2%


5-Year Cumulative Returns

-35.0%


3-Year Cumulative Returns

What are the long-term rolling returns for IOVA?

FIve years rolling returns for Iovance Biotherapeutics.

Which funds bought or sold IOVA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
821,000
821,000
0.01%
2022-11-21
FourThought Financial, LLC
ADDED
2.1
-3,000
26,000
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-2.4
-279,000
1,542,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-16,000
-
-%
2022-11-15
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
NEW
-
285,000
285,000
-%
2022-11-15
STATE STREET CORP
REDUCED
-15.62
-34,799,000
95,150,000
0.01%
2022-11-15
Clearstead Advisors, LLC
UNCHANGED
-
-1,000
-
-%
2022-11-15
NOMURA HOLDINGS INC
REDUCED
-57.31
-16,935,000
9,405,000
0.04%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
ADDED
262.8
2,680,730
3,928,630
0.01%

1–10 of 43

Latest Funds Activity

Are funds buying IOVA calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own IOVA

Iovance Biotherapeutics News

Yahoo Finance

DelveInsight Evaluates a Robust Osteosarcoma Pipeline as 30+ Influential Pharma Players to Set Foot in the Domain.5 days ago

IOVA Fair Value

Recent SEC filings of Iovance Biotherapeutics

View All Filings
Date Filed Form Type Document
Nov 18, 2022
8-K
Current Report
Nov 18, 2022
8-K
Current Report
Nov 18, 2022
424B5
Prospectus Filed
Nov 03, 2022
8-K
Current Report
Nov 03, 2022
10-Q
Quarterly Report
Sep 12, 2022
8-K
Current Report
Aug 29, 2022
8-K
Current Report
Aug 25, 2022
4
Insider Trading

Latest Insider Trading transactions for IOVA

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-08-23
MCPEAK MERRILL A
ACQUIRED
226,000
5.65
40,000
-
2022-06-14
BILINSKY IGOR
SOLD (Taxes)
-72,244.6
7.73
-9,346
Chief Operating Officer
2022-06-14
GRAF FINCKENSTEIN FRIEDRICH
SOLD (Taxes)
-52,633.6
7.73
-6,809
Chief Medical Officer
2022-06-14
GRAF FINCKENSTEIN FRIEDRICH
ACQUIRED
-
-
19,690
Chief Medical Officer
2022-06-14
BILINSKY IGOR
ACQUIRED
-
-
18,850
Chief Operating Officer
2022-06-14
Bellemin Jean-Marc
SOLD (Taxes)
-72,244.6
7.73
-9,346
Chief Financial Officer
2022-06-14
Bellemin Jean-Marc
ACQUIRED
-
-
18,850
Chief Financial Officer
2022-06-01
Rothbaum Wayne P.
BOUGHT
3,215,500
6.431
500,000
-
2022-06-01
Vogt Frederick G
BOUGHT
6,440
6.44
1,000
Interim CEO & General Counsel
2022-05-31
MCPEAK MERRILL A
BOUGHT
68,400
6.84
10,000
-

1–10 of 50

Frederick G. Vogt
320
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

IOVA Income Statement

2022-09-30
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Costs and expenses    
Research and development$ 72,502$ 65,355$ 214,208$ 183,423
General and administrative27,89320,88777,63459,815
Total costs and expenses100,39586,242291,842243,238
Loss from operations(100,395)(86,242)(291,842)(243,238)
Other income    
Interest income, net7771201,268316
Net Loss$ (99,618)$ (86,122)$ (290,574)$ (242,922)
Net Loss Per Share of Common Stock, Basic$ (0.63)$ (0.55)$ (1.85)$ (1.60)
Net Loss Per Share of Common Stock, Diluted$ (0.63)$ (0.55)$ (1.85)$ (1.60)
Weighted Average Shares of Common Stock Outstanding, Basic157,817155,508157,404152,221
Weighted Average Shares of Common Stock Outstanding, Diluted157,817155,508157,404152,221

IOVA Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current Assets  
Cash and cash equivalents$ 118,366$ 78,229
Short-term investments241,807426,181
Prepaid expenses and other assets9,7113,546
Total Current Assets369,884507,956
Property and equipment, net100,746100,938
Operating lease right-of-use assets68,26868,983
Long-term investments091,588
Restricted cash6,4306,084
Long-term assets5961,784
Total Assets545,924777,333
Current Liabilities  
Accounts payable24,25527,377
Accrued expenses47,81956,766
Operating lease liabilities7,1715,057
Total Current Liabilities79,24589,200
Non-Current Liabilities  
Operating lease liabilities - non-current71,94365,474
Long-term note payable1,0001,000
Total Non-Current Liabilities72,94366,474
Total Liabilities152,188155,674
Commitments and contingencies
Stockholders' Equity  
Common stock, $0.000041666 par value; 300,000,000 shares authorized, 157,840,581 and 157,004,742 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively77
Accumulated other comprehensive loss(2,038)(601)
Additional paid-in capital1,858,7831,794,695
Accumulated deficit(1,463,019)(1,172,445)
Total Stockholders' Equity393,736621,659
Total Liabilities and Stockholders' Equity545,924777,333
Series A Convertible Preferred Stock  
Stockholders' Equity  
Preferred stock, Value00
Series B Convertible Preferred Stock  
Stockholders' Equity  
Preferred stock, Value$ 3$ 3